Key result
Thrombomodulin immunostaining was positive in 96 of 106 primary transitional cell carcinomas, distinguishing them from renal cell carcinomas and adenocarcinomas, but not squamous cell carcinomas.
Why the study?
Does immunostaining for Thrombomodulin (TM) have practical value in the diagnosis of transitional cell carcinomas (TCCs)?
Observational (n=368)
Does immunostaining for Thrombomodulin (TM) have practical value in the diagnosis of transitional cell carcinomas (TCCs)?
Thrombomodulin immunostaining is a sensitive marker for transitional cell carcinoma and can help distinguish it from renal cell carcinomas and certain adenocarcinomas, but not from squamous cell carcinomas.
Answers are grounded in this paper and cite their sources.
Thrombomodulin immunostaining may aid TCC differentiation from RCC and adenocarcinomas; cross-sectional data leave its routine diagnostic role open pending validation.
Thrombomodulin (TM) is a surface glycoprotein reported to be expressed in a variety of tumors, including mesotheliomas, endothelial vascular tumors, squamous carcinomas, and various adenocarcinomas. This study evaluated TM expression in transitional cell carcinomas (TCCs) and determined whether immunostaining for TM has practical value in the diagnosis of TCCs. TM expression was observed in 96 of 106 primary tumors (bladder, 64/72; renal pelvis, 12/14; ureter, 3/3; prostate, 17/17) and in 21 of 23 metastatic TCCs. Among the adenocarcinomas, only 3 of 18 originating in the bladder, 7 of 46 in the lung, 4 of 21 in the breast, 2 of 24 in the ovary, and 2 of 4 in the pancreas expressed this marker. No staining was observed in the 22 renal cell carcinomas or the 35 adenocarcinomas of the prostate, 13 of the endometrium, or 12 of the colon. Nearly all squamous cell carcinomas (lung, 21/27; skin, 7/7; uterine cervix, 6/6; esophagus, 2/2; bladder, 2/2) reacted for TM. TM is a sensitive marker for TCC. TM immunostaining can assist in distinguishing this tumor from others, especially renal cell carcinomas and adenocarcinomas of the prostate, colon, and bladder, but it has no value in separating TCC from squamous cell carcinomas.
No takes yet. Share an insight, caveat, or question.
Nelson G. Ordóǹez (1998) conducted an observational in Transitional Cell Carcinoma (n=368). Thrombomodulin immunostaining vs. Other tumor types (renal cell carcinomas, adenocarcinomas, squamous cell carcinomas) was evaluated on Thrombomodulin expression. Thrombomodulin immunostaining was positive in 96 of 106 primary transitional cell carcinomas, distinguishing them from renal cell carcinomas and adenocarcinomas, but not squamous cell carcinomas.
Synapse has enriched 10 related papers. Consider them for comparative context: